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Available online 3 August 2004780Most gene therapy approaches employ viral vectors for gene delivery. Ideally, these vectors should
be produced at high titer and purity with well-established protocols. Standardized methods to
measure the quality of the vectors produced are imperative, as are techniques that allow
reproducible quantitation of viral titer. We devised a series of protocols that achieve high-titer
production and reproducible purification and provide for quality control and titering of
recombinant simian virus 40 vectors (rSV40s). rSV40s are good candidate vehicles for gene transfer:
they are easily modified to be nonreplicative and they are nonimmunogenic. Further, they infect a
wide variety of cells and allow long-term transgene expression. We report here these protocols to
produce rSV40 vectors in high yields, describe their purification, and characterize viral stocks using
quality control techniques that monitor the presence of wild-type SV40 revertants and defective
interfering particles. Several methods for reproducible titration of rSV40 viruses have been
compared. We believe that these techniques can be widely applied to obtain high concentrations
of high-quality rSV40 viruses reproducibly.Key Words: SV40, recombinant SV40 vectors, gene therapy, production, titration, DI particles,
wtSV40 revertantsINTRODUCTION
Simian virus 40 (SV40) is an icosahedral nonenveloped
polyomavirus with a double-stranded circular DNA of 5.2
kb [1,2]. Several properties make SV40 a good candidate
to be used as a vector for gene therapy approaches: (i) it is
easily modified to be nonreplicative ([3–5], references
therein, and this report); (ii) it can be produced in large
quantities [3,4]; (iii) it infects almost every cell type that
has been tested, both dividing and quiescent [6–8]; (iv) it
is not immunogenic [9,10]; (v) it allows long-term
expression of the transgene [6,7,9–13]; (vi) its molecular
biology is well studied; and (vii) the effects in humans of
wild-type SV40 have been documented [14,15].
The advantages of SV40 as a gene therapy vector can
be explained by the SV40 replicative cycle. SV40 binds
the major histocompatibility complex class I (MHC I) at
the cell surface [16]. MHC I is present on most cell
types, explaining SV40Ts wide host range. Following
virus entry into the cell, MHC I is shed, which may
result in poor antigen presentation by SV40-infected
cells [17]. The virus enters the cell via a caveolar
pathway that delivers SV40 to a microtubular network
that transports the virion to the endoplasmic reticulum[17,18]. Since SV40 traverses nuclear pores, it can infect
nondividing cells productively. The SV40 genome is
released in the nucleus as a nucleosome-coated mini-
chromosome that can be integrated randomly into the
host genome [19,20].
SV40 uses the cell machinery for replication and
transcription. The SV40 early promoter drives expression
of one alternatively spliced gene that encodes the large T
antigen (Tag) and the small t antigen (tag) [2]. The late
promoter, on the opposite strand, controls expression of
the structural proteins, VP1, VP2, and VP3 (Fig. 1A). Both
promoters, together with the regulatory sequences, origin
of replication, and packaging signals, are located within
approximately 500 bases [2]. Several of their functions are
controlled by Tag. Tag is essential for genome replication
and for late promoter-driven transcription. It also binds
and inactivates p53 and the retinoblastoma protein,
thereby immortalizing cells in culture [21,22]. Tag is
mainly a nuclear protein, but it is produced in excess and
inserts into the cell membrane, where it is the major virus
antigen [23]. The Tag gene is removed to generate
recombinant SV40 viruses (rSV40) ([3,4] and this report).
This renders rSV40 replication deficient, nononcogenic,
and nonimmunogenic, because the major antigen is not1525-0016/$30.00
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FIG. 1. Schematic view of wtSV40 genome and strategy to construct recombinant SV40 plasmids. (A) The wtSV40 genome is a 5.2-kb double-stranded DNA with
an origin of replication that overlaps with the SV40 early promoter (SVEP) and a SV40 late promoter (SVLP). SVEP drives the expression of Tag genes that encode
Tag and tag proteins. SVLP controls VP1, VP2, and VP3 protein expression (Capsid genes). Polyadenylation sequences are indicated (pA). (B) Generation of
recombinant SV40 virus genomes. (1) Tag gene has been replaced by an ampicillin-resistance (Ampr) gene, a bacterial origin of replication, and a small polylinker
(ClaI and XhoI) in pSL-4 [37]. (2) A longer polylinker has been introduced under the SVEP of pSL-4 to construct pSL-4pL. The polylinker has unique sites (sites A
indicated in black: ClaI, BglII, NheI, XmaI, BclI, Sal I, and XhoI) and sites that can be found at both sides of the Ampr gene (sites B indicated in gray: Xba I, Not I,
SacII, and Sac I). (3) A transgene can be easily cloned with restriction sites A under the control of SVEP. (4) To produce recombinant SV40 genomes (prSVX), the
Ampr gene is removed with restriction sites B and the plasmid is circularized.
METHODdoi:10.1016/j.ymthe.2004.06.1014produced and capsid protein expression is not activated
[2]. Removal of the Tag gene also generates approxi-
mately 2.5 kb of free space in the SV40 genome to clone
transgenes. Removing the capsid genes creates approx-
imately 2.5 kb of additional space. Thus, recombinant
SV40 vectors can accommodate as much as 5 kb of
inserted DNA [24].MOLECULAR THERAPY Vol. 10, No. 4, October 2004
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have encouraged several groups to study its efficacy in
animal models. Ex vivo infection of hematopoietic stem
cells with rSV40 has permitted expression of multidrug
resistance gene 1, h-globin [8,25,26], and the surface
antigen of hepatitis B virus [7,27]. rSV40 vectors have
been used successfully in animal models for liver781
METHOD doi:10.1016/j.ymthe.2004.06.1014diseases like Crigler–Najjar syndrome type 1 [10]. In
addition, rSV40 has been employed for vaccination and
immunostimulation purposes ([9,28], and our unpub-
lished results or to block HIV replication using different
strategies [27–35].
Despite the great potential of rSV40 in gene therapy
protocols, few methods for rSV40 vector production,
purification, quality control, and titering have been
described. For example, published methods for wild-
type SV40 production and purification need to be
tested to see if they can be applied to rSV40 vectors
[36]. Recently, methods to produce rSV40 vectors that
do not analyze the factors influencing vector produc-
tion have been proposed [3,4]. We have compared and
modified several protocols to define a method that
yields high titers of Tag-deleted nonreplicating rSV40
viruses. The presence of contaminating wild-type (wt)
SV40 or defective interfering (DI) particles was analyzed
to control for quality of vector preparations. We have
also compared new or already described methods for
rSV40 titering. We believe that these protocols could
be widely used both in laboratories that already work
with rSV40 vectors and in groups that are tempted to
exploit the strengths of SV40 as a gene delivery
vehicle.
RESULTS
Manipulation of the Viral Genome
Generation of recombinant SV40 viruses lacking the Tag
gene is represented in Fig. 1B. We started with pSL-4, in
which the Tag open reading frame has been replaced by
the ampicillin-resistance gene and bacterial origin of
replication (Ampr; Fig. 1B1) [37]. We first introduced a
polylinker with seven unique restriction sites after the
SV40 early promoter (EP) of pSL-4 and four restriction
sites found at both sides of the Ampr gene, to generate
pSL-4pL (Fig. 1B2). The Ampr gene, which is required
only for bacterial selection, can thus be removed easily
once the desired transgene has been inserted (Fig. 1B3).
Also, the rSV40 genome can be efficiently circularized
(Fig. 1B4). We used this strategy to produce several
recombinant SV40 genomes. Luciferase and GFP DNAs
were cloned into pSL-4pL to produce prSVLUC and
prSVGFP as described under Materials and Methods.
These plasmids were used to produce SVLUC and SVGFP
recombinant viruses (rSVLUC and rSVGFP, respectively).
rSV40 Virus Production
Our recombinant SV40 genomes do not replicate in cells
that lack Tag, since Tag is essential for virus genome
replication and for transcription of capsid genes. There-
fore we analyzed the ability of different Tag-expressing
cell lines to produce rSV40s. The packaging cell lines
used were COS-1, COS-7, CMT4, and COT2, which were
all derived from CV-1 cells, and 293T, derived from 293782cells (see Materials and Methods for details). In all of the
cell lines tested Tag expression is constitutive except for
CMT4 and COT2, in which Tag is under the control of an
inducible metallothionein promoter [5,39].
We tested different transfection methods to intro-
duce rSV40 genomes into packaging cell lines: calcium
phosphate precipitation and coupling DNA to lipids
like Fugene and Lipofectamine. We used different
amounts of prSVGFP to transfect subconfluent cells
and 48 h after transfection monitored GFP expression
by FACS and visualized it by fluorescence microscopy.
In all cases, calcium phosphate precipitation gave
greater than or equal to fourfold more GFP-expressing
cells than did the other methods tested (data not
shown). Efficiencies of transfection with calcium phos-
phate for the different packaging cell lines were
comparable, except for 293T cells, which were trans-
fected three- to fivefold more efficiently (data not
shown). However, since 293T cells did not amplify
recombinant viruses as well as the simian cell lines
tested (see below), we used COS-1 cells to standardize
rSV40 virus production.
To check whether prSVLUC and prSVGFP plasmids
were able to produce rSV40 viruses, we transfected COS-1
cells with these plasmids. We collected media and cells 3,
5, or 7 days after transfection. We pooled both cells and
media and subjected them to three cycles of freezing and
thawing to break cell membranes and liberate the viruses.
Then we used these lysates to infect CV-1 cells. Forty-
eight hours postinfection we visualized GFP or lysed the
cells to measure luciferase activity. Luciferase expression
was higher in CV-1 cells infected with rSVLUC viruses
collected on day 3 than on day 5 or 7 (data not shown).
The rSVLUC viruses obtained were amplified by infection
of fresh COS-1 cells. Again, we observed luciferase activity
in CV-1 cells infected with rSVLUC viruses collected on
day 3, 5, or 7 post-COS-1 infection (Fig. 2A). We observed
the highest expression with day 3-collected viruses,
which is in agreement with the time required for wtSV40
to complete an infectious cycle in tissue culture monkey
cells.
We never observed GFP expression, however, when we
performed the same experiments with prSVGFP. For
reasons that are so far unknown, other groups working on
rSV40 have also failed to detect GFP expression from
rSVGFPviruses (A.Oppenheim,personalcommunication).
Wild-type SV40 infection is usually lytic in permissive
cells. If cell lysis is also very efficient in producer cells
infected with rSV40, most of the viruses should be found
in the supernatant. However, viruses that have been
released from lysed cells may also be attached to
neighboring cell membranes. To see if infectious viruses
can be found in both cell pellet and media, we collected
these fractions 3 days after infection of COS-1 cells with
rSVLUC. We used comparable amounts of both fractions
to transduce CV-1 cells and measured luciferase activityMOLECULAR THERAPY Vol. 10, No. 4, October 2004
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METHODdoi:10.1016/j.ymthe.2004.06.1014(Fig. 2B). Even if luciferase activity was higher in CV-1
cells infected with the fraction containing the cell pellet,
both fractions yielded high levels of luciferase activity.FIG. 2. Development of a method to produce rSV40 viruses.(A) Quantitation of lu
rSVLUC viruses were used to infect COS-1 cells and recombinant virus amplificatio
and lysed. The activity of recombinant viruses was quantified by infection of CV-1
Statistical analysis shown at the top of the graphic indicates significant (*) and no
viruses that accumulated 3 days after infection in COS-1 cells or supernatant. COS
separated from the supernatant fraction. Both fractions were lysed and comparab
titrated by measurement of luciferase activity. (C) Quantitation of luciferase-ex
rSVLUC viruses were amplified for two rounds in COS-1, COS-7, CMT4, and 293
cells in which luciferase activity was measured. The significant difference found be
expression of COS-1 and COT-2 cells. COT-2 cells were induced with heavy met
fixed and an immunofluorescence assay with anti-Tag antibody was carried out (
luciferase-expressing rSVLUC viruses produced in COS-1 cells infected once or thr
once or every 12 h three times with the regular amount or half the amount of rSV
luciferase activity was measured. (F) Quantitation of luciferase-expressing rSVLUC
activity was measured in CV-1 cells infected with virus produced after each rou
twice. Error bars indicate standard deviations.
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packaging cell line. We amplified viruses produced in
COS-1 cells twice in COS-1, COS-7, CMT4, COT2, or 293Tciferase-expressing rSVLUC viruses produced in COS-1 cells for 3, 5, or 7 days.
n was allowed for 3, 5, or 7 days. Then, cells and supernatants were collected
cells in which luciferase activity was measured in relative luciferase units (RLU).
nsignificant (ns) differences. (B) Quantitation of luciferase-expressing rSVLUC
-1 cells were infected with rSVLUC. 3 days after infection the cellular pellet was
le amounts were used to infect CV-1 cells in which recombinant viruses were
pressing rSVLUC viruses amplified in COS-1, COS-7, 293T, and CMT4 cells.
T cells. After each round of infection, viruses were titrated by infection of CV-1
tween 293T and CMT4 cells and COS cells is indicated with an asterisk. (D) Tag
als as described [39]. COT-2 cells (c, d) or uninduced COS-1 cells (a, b) were
a, c). Staining with DAPI of the same fields is shown (b, d). (E) Quantitation of
ee times consecutively with two different viral doses. COS-1 cells were infected
LUC virus. The viruses produced were titrated by infecting CV-1 cells in which
viruses produced after four rounds of amplification in COS-1 cells. Luciferase
nd of amplification. All the experiments were done in triplicate and repeated
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as described under Materials and Methods. After each
round of viral amplification, we titrated viruses able to
express the transgene by infection of CV-1 cells in which
luciferase activity was measured. The results indicate that
COT2 (data not shown), CMT4, and 293T cells are not as
effective as COS cell lines in producing luciferase-express-
ing rSV40 vectors (Fig. 2C). Also, even though COS-1 and
COS-7 amplified rSVLUC viruses to similar extents in a
first round of infection, COS-1 cells produced more
luciferase-expressing virus in a second round of amplifi-
cation (Fig. 2C). Therefore we used COS-1 cells for rSV40
virus production.
As Tag is required for virus replication, we compared
Tag expression in the different packaging cell lines.
While all COS cells expressed Tag to a similar extent,
heavy metal-induced COT2 cells expressed different
levels of Tag (compare a and c in Fig. 2D). Also, some
COT2 cells showed undetectable levels of Tag (compare
c and d in Fig. 2D). Heavy metal-induced CMT4 and
COT2 cells produced similar amounts of Tag, as deter-
mined by immunofluorescence analysis (data not
shown).
We compared rSVLUC production by infection of
COS-1 cells, once or three times consecutively. We
used the viruses produced to infect CV-1 cells in
which luciferase activity was measured. The results
indicate that the highest virus production in terms of
luciferase activity was obtained with a single infection
(Fig. 2E). By infecting with half the amount of virus,
we reduced detected luciferase activity also by half
(Fig. 2E). Increasing the amount of virus used to infect
did not significantly increase the amount of luciferase-
expressing vector produced (data not shown). Surpris-
ingly, when cells were infected three times consec-
utively, luciferase activity in CV-1-infected cells
decreased.
Finally, we wanted to know how many rounds of virus
amplification could be done without altering rSV40
yields. We carried out four rounds of amplification in
COS-1 cells. After each round, luciferase activity was
measured in rSVLUC-infected CV-1 cells. We found that
virus could be amplified for up to three rounds, as the
products of the fourth round gave much less luciferase
activity (Fig. 2F).FIG. 3. Titration of rSVLUC viruses. (A) Titration by luciferase activity measuremen
serial dilutions of rSVLUCp3. Titer was calculated with the highest dilution that sho
PCR. CV-1 cells were mock infected (MOCK, b and d) or infected with 10-fold seri
viral DNA was hybridized with a biotinylated probe and developed with strepta
(105, a and c) as indicated at the left. The quantitation of the result indicates th
1010 infective units/ml as indicated at the top. (C and D) Titration of viral partic
luciferase transgene (D) were used. Standards are 10-fold serial dilutions of prSVLU
standards are connected with a line. Amplification value of 2 Al of water is show
Amplification of 2 Al of each viral stock is shown. The amplification values of vira
indicated as particles/ml in Table 1. The amplifications were done more than
deviations.
784After the third round of infection viruses were purified
by sucrose gradient ultracentrifugation as described
[3,4,36]. We have tested several modifications of the
protocol but could improve virus yield only when we used
a Dounce homogenizer to break cell membranes. This
increased 1.5 times the amount of luciferase produced in
rSVLUC-infected CV-1 cells (data not shown).
rSV40 Titration and Quality Controls
Measurement of luciferase activity in rSVLUC-infected
CV-1 cells is an easy way to quantitate luciferase-express-
ing rSVLUC viruses. To determine the titer of rSVLUC
stocks, we infected COS-1 cells with serial 1:3 dilutions of
rSVLUC and measured luciferase expression 48 h post-
infection. We used the higher dilution that yielded
luciferase activity to calculate virus titer as described [5],
resulting in 1.2  109 F 1.4  108 transducing units/ml
(Fig. 3A).
Measurement of luciferase activity, however, cannot
be applied to titrate vectors carrying other transgenes. So,
we compared two techniques to titrate rSV40 viruses: in
situ PCR, a method already described [3,4,36,43], and
real-time quantitative PCR. While in situ PCR counts
infective particles, quantitative PCR measures the num-
ber of rSV40 genomes. Titering of purified stocks of
rSVLUC by in situ PCR after three rounds of amplification
(rSVLUCp3) is shown in Fig. 3B. We obtained titers from
1  1010 to 1  1011 infectious units (iu)/ml in three
different stocks. For quantitative PCR we used a pair of
primers that amplify the region immediately after the
SV40 late promoter, so they can be used to titer different
rSV40 vectors (see Material and Methods). Using this
approach, we titered six different stocks of rSVLUCp3 and
obtained from 1.0  1010 to 1.2  1011 viral genomes/ml
(Fig. 3C and Table 1). We obtained similar titering results
with primers that amplified the luciferase gene (Fig. 3D
and Table 1). The presence of viral genomes lacking the
regions amplified by the two pairs of PCR primers used
cannot be excluded.
DI particles may be formed by replication or
recombination defects and amplified to high titers
due to their advantages in replication compared to
full-length viral genomes. If partial rSV40 genomes are
of an appropriate size they may be encapsidated
directly. Alternatively, they may be packaged togethert. Luciferase activity was measured 48 h after infection of COS-1 cells with 1:3
wed luciferase activity as described [5]. (B) Titration of infective units by in situ
al dilutions of a rSVLUCp3 viral stock. In situ PCR was carried out and amplified
vidin–peroxidase. Two different magnifications of a single dilution are shown
at the different rSVLUCp3 viral stocks tested have a titer of 5.5  1010 F 4.5 
les by quantitative PCR. Primers that amplify the SV40 late region (C) or the
C as indicated at the bottom of the graphic. Amplification values of each of the
n with a triangle (C) or was not detected and therefore is not indicated (D)
l stocks and water can be obtained by comparison with the standards and are
three times and the averages of several stocks are indicated with standard
MOLECULAR THERAPY Vol. 10, No. 4, October 2004
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virus amplification is decreased in the presence of DI
particles as they compete for the replication machi-MOLECULAR THERAPY Vol. 10, No. 4, October 2004
Copyright C The American Society of Gene Therapynery. Thus, the presence of DI particles could explain
the decrease in luciferase activity produced in CV-1
cells infected with a rSVLUC that has been amplified785
Table 1: Comparison of viral stocks titrated by quantitative PCR and luciferase activity in CV-1 cells
VPs part/ml LUC part/ml LUC activity
rSVLUCp3 6.30  1010 + 5.63  1010 1.93  1011 + 1.81  1011 6.99  106 m 1.45  106
rSVLUCp4 7.01  1011 F 1.22  1011 9.97  1010 F 6.54  1010 2.41  106 F 1.55  106
rSVLUCp2* 2.12  1012 F 9.40  1011 1.05  109 F 1.06  108 8.14  105 F 3.30  105
wtSV40p3 1.28  1012 F 5.98  1011 Non detected Non determined
Viral DNA isolated from rSVLUCp3, rSVLUCp4, rSVLUCp2*, and wtSV40 stocks was subjected to quantitative PCR using primers that amplified the SV40 late region (VPs) or the luciferas
transgene (LUC). The amplifications were done more than three times with each of six, four, and two different stocks of rSVLUCp3, rSVLUCp4, and rSVLUCp2*, respectively. Averages of th
results are indicated with standard deviations. Values were corrected to viral particles/ml and are plotted as a graphic. The activity of recombinant viruses was quantified by infection of CV-1
cells in which luciferase activity was measured. Measurements were done in triplicate and repeated more than twice for each stock.
METHOD doi:10.1016/j.ymthe.2004.06.1014four times (rSVLUCp4) compared to cells infected by
rSVLUCp3 (see Fig. 2E). We analyzed DI particle
contamination by Southern blot. Viral DNA isolated
from four different stocks of rSVLUCp3 or seven
different stocks of rSVLUCp4 was hybridized with
labeled probes containing the sequences of SV40 ori-
VP1 (Fig. 4) or luciferase (data not shown). DI particles
that carry the SV40 ori or SV40 late region (VPs) but
not the luciferase gene were initially detected in the
third round of viral amplification (lanes 4 to 7) and
increased significantly in the fourth round of amplifi-
cation (compare lanes 4–7 with lanes 8 and 10–15).
Quantitation of the Southern blot indicates that the DI
particles represent 2.3 F 2.8% of passage 3 rSVLUC
stocks and 36.2 F 8.9% of passage 4 rSVLUC prepa-
rations. Surprisingly, DI particles were not detected in
passage 3 wtSV40 stocks (lane 9). The presence of DI
particles lacking the sequences used as probes (SV40
ori-VP1 and luciferase) or whose difference in size is
not detected by Southern blot cannot be excluded.
The quality of a recombinant virus stock can be
measured by the amount of infectious units/viral
genomes or the amount of DI particles and also by the
amount of particles containing recombinant wtSV40
sequences (rwtSV40) that may contaminate the rSV40
viral stocks. Recombinant wtSV40 can be formed by
homologous recombination between the rSV40 DNA
and the COS-1 cell genome in which a full-length SV40
virus mutated in the origin of replication has been
integrated [45]. We analyzed the presence of rwtSV40
DNA by Southern blotting of viral DNA from rSVLUC.
We used wtSV40 DNA as positive control. The Southern
blot was hybridized with labeled probes containing theMOLECULAR THERAPY Vol. 10, No. 4, October 2004786
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esequences of SV40 ori-VP1 (Fig. 4), luciferase (data not
shown), or Tag (Fig. 5A). However, rwtSV40 was not
detected in rSVLUC stocks (compare Figs. 4 and 5A,
lanes 4–8). To increase the sensitivity of detection we
attempted to amplify Tag from rSVLUC DNA using
diluted wtSV40 DNA as a positive control. Again, we
did not detect rwtSV40 viral DNA in rSVLUC stocks (Fig.
5B, compare lane 5 to lane 4). We also analyzed the
presence of rwtSV40 by quantitative PCR using Tag
oligonucleotides. The level of rwtSV40 contamination in
passage 3 rSVLUC stocks was below the limit of
detection (data not shown). Finally, rSVLUCp4 stocks
or viral stocks obtained in two rounds of amplification
maintained for 7 days each in COS-7 cells (rSVLUCp2*)
were contaminated with replication-competent rwtSV40
viruses, as they could be amplified in CV-1 cells (data
not shown). However, rwtSV40 viruses were not
detected after four amplifications of 3  108 iu of
rSVLUCp3 in CV-1 cells infected for longer than 1 week.
As this technique was sensitive enough to detect a single
wtSV40, we conclude that contamination is lower than
1 rwtSV40 per 3  108 infectious units of rSVLUCp3.
DISCUSSION
We devised protocols to produce and purify large
amounts of high-quality recombinant SV40 vectors (Fig.
6). Our starting plasmid, pSL-4pL, carries a wtSV40
genome lacking Tag, but with early promoter and
polyadenylation signals intact. As effective encapsidation
is possible for SV40 genomes V5.7 kb, insert sizes for these
vectors should be smaller than 3.0 kb [24]. Additional
modifications can be made to increase rSV40 inserty
FIG. 4. Detection of DI particles. Southern blot of viral DNA hybridized with a SV40 ori-VP1 probe. DNAs tested were salmon sperm DNA (MOCK), plasmids
prSVLUC and pwtSV40, and viral genomes rSVLUCp3, rSVLUCp4, and wtSV40p3 as indicated at the top. The size of molecular weight markers is indicated on the
left. Arrows on the right indicate the positions of full-length viruses and DI particles.
METHODdoi:10.1016/j.ymthe.2004.06.1014capacity. The SV40 capsid genes may be deleted, since
expression of these genes can be provided in trans by COS
cells ([24] and data not shown). Thus, inserts up to 5 kb
may be accommodated.
Once the transgene has been cloned, the ampicillin-
resistance gene is deleted and the producer plasmid is
circularized to transfect COS-1 cells. Transfection does
not seem to be a limitation to produce high titers of
rSV40 viruses: the virus stocks produced by transfection
are expanded by infecting COS-1 cells for up to three
rounds of amplification (Fig. 6). This means that a
single transfection of 6 Ag of plasmid could produce up
to 10 L of viruses, as every round of viral amplification
produces a 10-fold increase in the volume of the viral
mix.
We do not know why COS-1 cells were the most
effective packaging cells in these studies. All the
packaging cells tested are from SV40-susceptible mon-
key kidney origin (CV-1) except the 293T cells. Also, all
cell lines but COT2 and CMT4 expressed similar levels
of Tag (Fig. 2D and data not shown). It was reportedFIG. 5. Detection of recombinant wtSV40. (A) Southern blot of viral DNA hybrid
markers are indicated on the left. The arrow on the right indicates the position
salmon sperm DNA (MOCK), plasmids prSVLUC and pwtSV40, and viral genome
are indicated on the left. Tag amplified sequences are seen at approx. 150 pb.
MOLECULAR THERAPY Vol. 10, No. 4, October 2004
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to 7 wtSV40 genomes, mutated at the origin of
replication [38,45]. However, there may be considerable
variation in these cell lines, depending on their origin.
Thus, multiply passaged COS-7 cells from ATCC were
shown to have only 1–2 copies of integrated wtSV40
DNA, while EACC-derived COS-7 had 3–4 copies of
wtSV40 DNA, which increased to up to 12 copies upon
passage (data not shown). It has been reported that
such COS-7 cells have a higher probability than COS-1
cells of homologous recombination that produces
rwtSV40 viruses [45]. These may contaminate viral
stocks packaged in COS-7 cells so that recombinant
viruses cannot be productively amplified. Using PCR,
and testing for growth in CV-1 cells, we have observed
heavy rwtSV40 contamination in rSVLUC viral stocks
grown for 7 days and amplified twice in COS-7 cells
(data not shown). These data differ from those of some
other investigators using COS-7 cells from other
sources ([24]; D. S. Strayer, unpublished data; L.
Couture, personal communication).ized with a Tag probe. Samples are as in Fig. 4. The sizes of molecular weight
of wtSV40 viral DNA. (B) PCR of viral DNA to amplify Tag. DNAs tested were
s rSVLUCp3 and wtSV40p3 as indicated. The sizes of molecular weight markers
787
FIG. 6. Method for rSV40 vector production. (1) prSV40 is transfected into COS-1 cells by calcium phosphate precipitation. (2) Three days after transfection
cells and supernatant are collected and frozen and thawed three times. (3) 1 ml of the virus mix is used to infect fresh COS-1 cells. (4) Three days after
infection viruses are collected as in step 2 and a new round of infection is done as before. (5) After a final round of infection is done, viruses are collected and
purified.
METHOD doi:10.1016/j.ymthe.2004.06.1014Similarly, our data for COS-1 cells are divergent from
studies reported by some other groups [45]. A ratio of 1
rwtSV40/1000 rSV40 viruses was noted after three
rounds of amplification in COS-1 cells [5]. However,
we did not detect rwtSV40 until four rounds of
amplification in COS-1 cells. We believe that these
differences may reflect the short time (3 days) we
allowed viruses to replicate, compared to other protocols
(5, 7, or even 14 days). We found that such longer
incubations did not increase virus titer (see Fig. 2B), but
they may increase the chances for homologous recom-
bination to generate wtSV40.
rSVLUCp4 viral stocks were less effective than stocks
from earlier passages. This may be because high-passage
stocks had rwtSV40 and DI particles, which may have
decreased effective luciferase expression (Figs. 2F and 4
and Table 1). Also, packaging cells may progressively
inactivate a transgene, e.g., by methylation. It may be for
this reason that we and others have been unable to
produce rSV40s expressing GFP (this work, [23], and Arad
and Oppenheim, personal communication) or thymidine
kinase (data not shown) from packaging cell lines. In vitro
packaging appears to be the only way to produce GFP-
expressing rSVGFP [26].
Formation of DI particles when producing rSV40
viruses has important implications. Several groups have
designed Tag-expressing cells lines with a decreased risk
of homologous recombination to produce rwtSV40 par-
ticles ([5] and D. S. Strayer, unpublished), but DI particles
may continue to be made in these settings. Purification788protocols that can separate full-length rSV40 viruses from
DI viruses may help address this problem. It is also of
note that we did not detect DI particles in wtSV40p3
viruses, suggesting that the multiplicities of infection
that we are using for viral production are not a direct
cause of DI particle formation.
We found that rSV40 vector stocks produced accord-
ing to our protocols should not be amplified more than
three times, to maximize expression and to minimize the
formation of DI particles or wtSV40 revertants (Figs. 2F, 4,
and 5). Vector titers achieved were on the order of 1011/
viral particles/ml. Over 10 other rSV40s produced in the
laboratory gave titers and quality similar to those
ofrSVLUCp3, indicating that luciferase DNA or expres-
sion does not affect viral production (data not shown and
M.V. et al., manuscript in preparation).
There may not be an ideal method for titering rSV40
vectors. In situ PCR is the method used so far for
titration of rSV40 infective particles, but the specificity
of this approach for quantitating vector genomes is a
function of the specificities of the PCR primers used.
Therefore we tested real-time quantitative PCR, using
two sets of primers, one specific for VPs sequences and
another that amplified transgene sequences. Combined,
these analyses can provide information about the
quality of the particles: similar results with VP primers
and LUC primers allow accurate quantitation of
rSVLUCp3 particles. If the two primer sets give different
numbers, as for rSVLUCp2*, lower quality stocks are
likely.MOLECULAR THERAPY Vol. 10, No. 4, October 2004
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METHODdoi:10.1016/j.ymthe.2004.06.1014Similar results were obtained by in situ PCR and by
quantitative PCR or when quantitative PCR was used to
quantify rSVLUC genomes in infected cells (data not
shown). The last technique was used after cell fractiona-
tion in nucleus and cytoplasm to reveal that 24 h after
infection 70% of rSVLUC genomes are in the nuclear
fraction (data not shown). However, not all rSVLUC
genomes express the transgene. If a direct comparison
can be made, of the 1.0  1010 to 1.2  1011 infective
genomes only 1.2  109 F 1.4  108 express luciferase as
titered by measurement of luciferase activity. Silencing of
the transgene, e.g., by methylation, could explain this
phenomenon.
Protocols for rSV40 production and titration described
here offer methods for preparation of high-titer, good-
quality, nonreplicative rSV40 viruses. We have found
these vectors to be very efficient in different cell types in
vitro and in vivo (data not shown). Our methods may help
laboratories working with rSV40s and encourage new
laboratories to try this promising vector system.
MATERIALS AND METHODS
Cloning procedures. pSL-4 plasmid (kindly provided by S. de la Luna)
contains SV40 sequences in which the large T antigen gene was replaced
by the ampicillin-resistance gene and a small polylinker [37]. We first
wanted to increase the number of restriction sites in the polylinker to
facilitate easy cloning of transgenes and simple removal of the Ampr gene.
To that end, we introduced two hybridized oligos with polylinker
sequences at pSL-4 sites ClaI and XhoI, located between the SV40 EP
and the 5V end of the Ampr gene, to generate pSL-4pL (Fig. 1B1). The
polylinker contains the unique sites ClaI, BglII, NheI, XmaI, BclI, SalI, and
XhoI close to the EP sequences and sites XbaI, NotI, SacII, and SacI, which
are also found at the other end of the Ampr gene (Fig. 1B2). Positive clones
were selected and the polylinker was verified by sequencing (ABI Prism
310 genetic analyzer from Perkin–Elmer).
To generate a recombinant SV40 virus with the luciferase transgene
(rSVLUC), firefly luciferase gene was extracted with StuI and SalI from
pGL3 plasmid (Promega) and cloned into the same restriction sites of
pSL-4pL. To generate a recombinant SV40 virus with GFP (rSVGFP),
pEGFP-N1 (Clontech) was digested using SalI and NotI, and the GFP gene
was cloned at the same restriction sites of pSL-4pL. The resulting
plasmids, named prSVLUC and prSVGFP, respectively, were verified by
restriction analysis.
Cell lines. COS-1 and COS-7 (ECACC) [38] cell lines derive from the
monkey kidney fibroblast CV-1 cell line by integration of mutated SV40
genomes. CMT4 [39] and COT2 cells (kindly donated by A. Oppenheim)
are Tag-expressing cells derived from CV-1 cells in which expression of
Tag is under the control of the heavy-metal-inducible murine metal-
lothionein promoter [5]. The human embryonic kidney fibroblast cell
line 293T cells (donated by I. Narvaiza) constitutively express Tag. All
cell lines were grown in culture using DulbeccoTs modified EagleTs
medium (DMEM) (Gibco BRL/Life Technologies) supplemented with
10% fetal bovine serum (FBS) (Gibco BRL/Life Technologies), penicillin–
streptomycin, and glutamine as recommended. COS-1, COS-7, 293T,
CMT4, and COT2 cells were used to expand rSV40 viruses because of
their ability to express Tag.
Virus production. Transfections were done by calcium phosphate
precipitation, Fugene (Roche), or Lipofectamine (Invitrogen) as recom-
mended by the suppliers. Six micrograms of the rSV40 plasmid were
used to transfect 3.5  106 cells previously washed with DMEM 2% FBS.MOLECULAR THERAPY Vol. 10, No. 4, October 2004
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subjected to three cycles of freezing and thawing to break cell
membranes and liberate the virus. One milliliter of this lysate was then
used to transduce fresh cells. Cells (3.5  106) were washed twice with
PBS (Gibco BRL/Life Technologies) and incubated with 1 ml of the lysate
for 2 h at 378C. Then, the lysate was removed and cells were grown in
DMEM 2% FBS for 72 h, when the cells and supernatant were harvested.
This virus amplification cycle was repeated twice using identical
conditions.
Virus purification. rSV40 viruses were purified as described [3,4,36].
Briefly, 3.5  106 infected cells were harvested in a total volume of 10 ml
of cell debris and media. One milliliter of 10% Triton X-100 and 5%
sodium deoxycholate was added to dissociate the virus from cell
membranes, and a Dounce homogenizer was used to disaggregate cell
membranes. Cell debris was removed by centrifugation at 16,000g for 20
min. The virus present in the supernatant was concentrated in a
discontinuous sucrose gradient (1.5 ml of 75% sucrose and 2.5 ml of
20% sucrose) by centrifugation at 23,000 rpm for 3.5 h in an SW28.1 rotor
(Beckman). Eight fractions of 0.5 ml were collected by piercing the
bottom of the tube. Fractions 4 to 6 were pooled and dialyzed against PBS
overnight at 48C and using sterile conditions.
Viral DNA analysis. To isolate viral DNA, 800 Al of a standard stock of
purified virus was incubated in 0.01% SDS, 25 mM EDTA at pH 8.0 and
0.84 mg/ml of proteinase K (Roche) for 3 h at 378C. After phenol
extraction, viral DNA was precipitated with ethanol.
Titration of rSVLUC was done by three different methods: in situ PCR,
quantitative PCR, and luciferase activity measurement. In situ PCR was
used to titrate rSVLUC infection units as described [3,4]. Briefly, 5  105
CV-1 cells were transduced or mock transduced with 10-fold serial
dilutions of the virus stock. Twenty-four hours after transduction cells
were collected, bound to slides, and fixed in paraformaldehyde. After
proteinase K treatment, in situ PCR was done using primers that hybridize
specifically with the SV40 late promoter region: SV40 4.1 (5V-
ACACCTGGTTGCTGACTAAT-3V) a nd SV40 4 .2 (5V-CAG-
TATCTTCCCCTTCACAAA-3V). The PCR product was denatured and
hybridized to a biotinylated DNA probe (5V-AACTGACACCATTCCA-
CAGCTGGTTCTTTCCGCCTCAGAA-3V). In situ PCR was developed with
a streptavidin–peroxidase solution.
Titration of rSV40 particles was done by quantitative PCR [40]. Two
different pairs of primers and probes were used. To amplify the SV40 late
region, the primers used were SV394S (5V-GGTTATTTGAGGCCATGGTG-
3V) and SV460AS (5V-GATGACCTACGAACCTTAAC-3V), and the SV probe
(5V-TAACTGACACACATTCCACAGCTGGTTCTTTCCGCCTCAGA-3V). To
amplify the luciferase transgene we used primers LUC1F (5V-AACATAAA-
GAAAGGCCCGGC-3V) and LUC1R (5V-GCCTTATGCAGTTGCTCTCCA-
3V) and the probe SLUC (5V-CATTCTATCCGCTGGAAGATGGAACCG-3V).
The quantitative PCR was done with 10-fold serial dilutions of the
prSVLUC plasmid as standards, 2 Al of distilled water as a negative control,
and 2 Al of each viral DNA. The PCR was done following the instructions
of the manufacturer (Light Cycler; Roche). The following conditions were
used: 958C for 10 min and 40 cycles at 958C for 10 s, 408C for 1 min, and
608C for 20 s.
PCRs were performed to test for the presence of recombinant wild-
type SV40 in rSVLUC viral stocks. A pair of primers was used to amplify
100 bp between the SV40 EP and the Tag (SVEP, 5V-CTCGGCCTCTGAGC-
TATTCC-3V, and TAG, 5V-CCCCCAGGCACTCCTTTC-3V). The wtSV40
genome (kindly provided by J. Ortı´n) was used as a positive control and
viral DNA from rSVLUC was assayed. The following conditions were used:
948C for 2 min and 27 cycles at 948C for 30 s, 608C for 1 min, and 728C for
15 s and a final extension at 728C for 6 min.
The presence of rwtSV40 in rSVLUC viral stocks was also tested by
quantitative PCR. Conditions used were the same as described above. Tag
was amplified with primers Tag3944S (5V-ACATCCCAAGCAATAACAA-
CACA-3V) and Tag4028AS (5V-GGAAACTAAACAAGTGTCCTGGAAG-3V)
and quantified with the probe TTAQ (5V-CATCACATTTTGTTTCCATTG-
CATACTC-3V).789
METHOD doi:10.1016/j.ymthe.2004.06.1014Southern blots [41] were done to test for the presence of defective
SV40 particles and rwtSV40 in rSVLUC viral stocks. The blots were
hybridized with an SV40 origin of replication and VP1 probe (SV40ori-
VP1) a Tag and/or a luciferase probe. SVori-VP1 DNA was obtained by ClaI
and BamHI digestion of prSVLUC, Tag by PCR of wtSV40 viral DNA with
Tag4228S (GGAGCAGTGGTGGAATGC) and Tag3640AS (GTGTAGC-
CAAGCAACTCCA), and luciferase by StuI and SalI digestion of pGL3
plasmid. Probes were labeled with [32P]dCTP with a random-primed DNA
labeling kit (Roche). Prehybridization was performed at 608C for 2 h in 5
mM EDTA, 0.75 M NaCl2, 0.5% SDS, 50 mM Tris, and 200 Ag/ml tRNA and
the membrane was then hybridized to the probe for 14 h at 608C. Finally,
the membrane was washed three times with 2 SSC and 0.1% SDS at 608C
and radioactivity bound to the membrane was visualized by autoradiog-
raphy (Hyperfilm; Kodak) and phosphorimager analysis (Cyclone; Perkin–
Elmer).
Protein analysis. GFP expression was analyzed 48 h after transfection or
infection of CV-1 or COS cells with prSVGFP or rSVGFP, respectively. Cells
were washed and fixed with 4% paraformaldehyde in CSK buffer as
described [42]. Cells were mounted and fluorescence was observed in a
microscope (Nikon) or by FACS (Becton–Dickinson). Immunofluores-
cence assays to detect Tag were done with a 1:500 dilution of a
monoclonal anti-Tag antibody (provided by J. Ortin) and an anti-mouse
secondary antibody labeled with Cg3 and diluted 1:200 (Sigma). DNA was
stained with DAPI (Vectashield; Vector Laboratories).
The Simple-Luciferase Reporter Assay System (Promega) was used to
measure luciferase activity from cells transfected with prSVLUC or
transduced by rSVLUC viruses. Normally, 100 Al of virus stock was used
to infect 0.2 million CV-1 cells. Luciferase activity was also used to
quantify rSVLuc transducing units by infecting 1.5  105 COS-1 cells with
serial 1:3 dilutions of rSVLUC stocks. Forty-eight hours after infection
cells were harvested and luciferase activity was measured in a lumin-
ometer (Berthold LB9507) following the recommendations of the
supplier. In all cases dilutions of the virus or dilutions of the extracts
were made to discard saturation of the luciferase activity (data not
shown).
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